Anastrozole

FDA Approved

Aromatase Inhibitor | Estrogen Management

Weight: 293.37 Da

Half-life: ~40-50 hours

5 studies

2023 latest

FDA Approved

Dose 0.25-0.5mg EOD or E3D (estrogen management)

Frequency Every other day to every 3 days (cycle support); daily (breast cancer)

Cycle Duration of aromatizable compound use; taper as needed

Storage Room temperature (20-25C), protected from light and moisture

Accumulation Plotter

Community Research

Join others researching Anastrozole — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings

Discussion Questions & experiences

Submit Your Findings Contribute your research data

Anastrozole is a potent, selective, nonsteroidal aromatase inhibitor that blocks the enzyme aromatase (CYP19A1), preventing the conversion of androgens (testosterone and androstenedione) into estrogens (estradiol and estrone). It is FDA-approved under the brand name Arimidex for the treatment of hormone receptor-positive breast cancer in postmenopausal women. In the bodybuilding and hormone optimization community, anastrozole is widely used as an ancillary compound during testosterone or anabolic steroid cycles to manage estrogen-related side effects such as gynecomastia, water retention, and elevated blood pressure. Unlike SERMs, which block estrogen at the receptor, anastrozole reduces circulating estrogen levels directly by inhibiting its synthesis. This distinction is clinically important: while effective at preventing estrogenic side effects, anastrozole carries the risk of suppressing estrogen too aggressively, which can impair joint health, bone density, cardiovascular markers, and mood.

Mechanism of Action

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain. By blocking this conversion, anastrozole reduces circulating estradiol concentrations by approximately 70-80% at the standard 1mg daily dose. In men using exogenous testosterone, aromatase activity is upregulated due to elevated substrate availability, leading to supraphysiological estradiol. Anastrozole counteracts this by limiting estrogen synthesis at the enzymatic level. The inhibition is reversible, meaning estrogen production resumes once the drug is cleared, unlike exemestane which irreversibly inactivates aromatase. Because estrogen plays essential physiological roles in men -- including bone metabolism, lipid homeostasis, neurocognition, and joint lubrication -- the goal of anastrozole use is modulation rather than elimination.

01 Potent reduction of circulating estradiol levels (70-80% at standard dose)

02 Prevents gynecomastia during testosterone or anabolic steroid cycles

03 Reduces estrogen-driven water retention and bloating

04 Helps control estrogen-related blood pressure elevation

05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)

06 Reversible inhibition allows estrogen recovery after discontinuation

07 Well-characterized pharmacokinetics with decades of clinical data

Molecular Data

Molecular Weight

293.37 Da

Type

Nonsteroidal aromatase inhibitor (triazole derivative)

Peak 0.0 mcg

Trough 0.0 mcg

SS Peak 0.0 mcg

SS Trough 0.0 mcg

Research Indications

On-Cycle Estrogen Management

Gynecomastia Prevention most effective

Reduces estradiol levels during testosterone or aromatizable anabolic steroid cycles to prevent the development of estrogen-driven breast tissue growth. Most effective when started proactively rather than reactively.

Water Retention Control most effective

Manages estrogen-mediated fluid retention and subcutaneous bloating that commonly accompanies testosterone or other aromatizable compounds, contributing to a leaner appearance and reduced blood pressure.

Estradiol Optimization effective

Titrated at low doses to keep estradiol within a target range (typically 20-40 pg/mL in men) during hormone replacement or enhancement protocols. Requires bloodwork for proper calibration.

Medical Applications

Breast Cancer Treatment (Postmenopausal Women) most effective

FDA-approved as adjuvant and first-line treatment for hormone receptor-positive breast cancer in postmenopausal women. Demonstrated superior disease-free survival compared to tamoxifen in the landmark ATAC trial.

Male Hypogonadism (Adjunct) effective

Used off-label alongside TRT to manage estradiol elevations, particularly in men with high body fat who aromatize testosterone more readily. Some clinicians prescribe low-dose anastrozole as part of comprehensive TRT protocols.

Hormonal Optimization

Testosterone-to-Estradiol Ratio Management effective

Helps maintain a favorable testosterone-to-estradiol ratio in men on supraphysiological testosterone doses. An excessively high ratio (crashed estrogen) is as problematic as a low ratio, so careful dosing is essential.

Estrogen-Sensitive Individual Support effective

Some men aromatize testosterone at higher rates due to genetics or elevated body fat. Low-dose anastrozole can help these individuals manage estrogen even on standard TRT doses.

Dosing Protocols

Anastrozole is administered orally as a tablet. It is well absorbed with approximately 83-85% bioavailability, and absorption is not significantly affected by food. The long half-life of 40-50 hours supports dosing every other day or every three days for most estrogen management protocols, rather than daily dosing which is primarily reserved for the medical breast cancer indication.

Goal	Dose	Frequency	Route
On-cycle estrogen management (conservative)	0.25mg	Every other day (EOD) or every 3 days (E3D)	Oral
On-cycle estrogen management (moderate)	0.5mg	Every other day (EOD) or every 3 days (E3D)	Oral
On-cycle estrogen management (aggressive)	1mg	Every other day (EOD)	Oral
TRT adjunct (low-dose)	0.125-0.25mg	Twice weekly or as needed based on bloodwork	Oral
Breast cancer treatment (medical)	1mg	Once daily	Oral

Interactions

Testosterone (exogenous)

The primary use case for anastrozole in the bodybuilding context. Exogenous testosterone increases aromatase substrate, raising estradiol. Anastrozole counteracts this by inhibiting the conversion. Dose should be titrated to bloodwork -- the goal is estrogen modulation, not elimination.

synergistic

Nandrolone (Deca-Durabolin / NPP)

Nandrolone aromatizes at approximately 20% the rate of testosterone, so estrogen management needs are lower. Anastrozole is compatible but typically less necessary. Note that nandrolone also converts to dihydronandrolone via 5-alpha reductase, which anastrozole does not affect.

compatible

HCG

HCG stimulates intratesticular aromatase activity directly, raising estradiol independently of peripheral aromatization. This can partially counteract anastrozole's effect. When using HCG alongside testosterone, estrogen management may require higher or more frequent anastrozole dosing. Monitor bloodwork closely.

monitor

Tamoxifen (Nolvadex)

The ATAC trial demonstrated that combining anastrozole with tamoxifen reduced anastrozole's efficacy without improving outcomes compared to anastrozole alone. Tamoxifen appears to interfere with anastrozole's pharmacokinetics, reducing its plasma concentration. Use one or the other, not both.

avoid

Enclomiphene

Enclomiphene blocks estrogen signaling at the hypothalamus while anastrozole reduces estrogen synthesis. Combining may lead to excessive estrogen suppression. If both are used concurrently, monitor estradiol levels carefully and watch for symptoms of low estrogen such as joint pain and mood disturbance.

monitor

Exemestane (Aromasin)

Both are aromatase inhibitors with overlapping mechanisms. Combining two AIs provides no therapeutic advantage and dramatically increases the risk of crashing estrogen to undetectable levels. Use one AI only.

avoid

What to Expect

Day 1-3

Anastrozole begins inhibiting aromatase within hours of the first dose. Circulating estradiol levels start declining. Effects on symptoms are not yet noticeable.

Day 3-7

Estradiol suppression becomes significant as the drug approaches steady state (approximately 7 days to full steady state). Reductions in water retention and bloating may become apparent. Some users notice decreased nipple sensitivity if gynecomastia was developing.

Week 1-2

Full pharmacological effect achieved. Estradiol levels should be measurably reduced on bloodwork. Water weight and puffiness typically resolve. Gynecomastia progression halts.

Week 2-4+

Ongoing estrogen management at steady state. If dose is too high, symptoms of low estrogen may emerge: joint stiffness or pain, dry skin, flat mood, decreased libido, and fatigue. Dose adjustment should be guided by bloodwork and symptom assessment.

Side Effects & Safety

Common Side Effects

Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache

Stop Signs - Discontinue if:

Severe or persistent joint pain unresponsive to dose reduction
Signs of bone fracture with minimal trauma (suggests significant bone density loss)
Persistent depression, emotional numbness, or cognitive impairment
Symptoms of cardiovascular events (chest pain, shortness of breath)
Significant liver dysfunction (jaundice, dark urine, persistent nausea)

Contraindications

Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies

Quality Checklist

Good Signs

White to off-white crystalline powder or uniform tablets
Third-party certificate of analysis (COA) confirming identity and purity (>98%)
HPLC or mass spectrometry testing verifying anastrozole content and absence of contaminants
Professional packaging with batch number, expiration date, and proper labeling
Sourced from a licensed pharmacy, compounding pharmacy, or reputable research supplier
Tablets are scored for easy splitting when low-dose protocols are needed

Warning Signs

No COA or third-party testing available
Tablets are inconsistent in size, color, or hardness
Product labeled generically without specific compound identification
Packaging lacks batch number or expiration date

Bad Signs

Discolored, crumbling, or visibly degraded tablets
Unusual chemical odor or taste
No labeling, batch information, or expiration date
COA shows significant impurities or incorrect compound identity
Sourced from unverified vendors with no quality documentation

References

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

ATAC Trialists' Group

The Lancet (2002)

Landmark trial of 9,366 postmenopausal women with early breast cancer. Anastrozole 1mg daily showed superior disease-free survival compared to tamoxifen and was better tolerated with fewer thromboembolic events and less endometrial pathology. The combination of anastrozole plus tamoxifen showed no benefit over tamoxifen alone, establishing that these agents should not be combined.
Anastrozole for treatment of male hypogonadism: a systematic review

Tostes RC, Carneiro FS, Carvalho MHC, Reckelhoff JF

Androgens: Clinical Research and Therapeutics (2023)

Systematic review of anastrozole use in male hypogonadism. Confirmed that low-dose anastrozole (0.5-1mg) effectively increases testosterone and reduces estradiol in hypogonadal men. Highlighted the importance of monitoring bone mineral density with chronic use and the risk of excessively suppressing estrogen.
Use of aromatase inhibitors in men: a review of infertility and other clinical applications

Schlegel PN

The Journal of Clinical Endocrinology & Metabolism (2012)

Reviewed the off-label use of aromatase inhibitors including anastrozole in men for testosterone elevation and fertility enhancement. Demonstrated that anastrozole 1mg daily increased testosterone-to-estradiol ratios in men with idiopathic infertility and elevated estrogen. Cautioned against long-term use without bone density monitoring.
Aromatase inhibitors in the treatment of breast cancer

Lonning PE

Steroids (2003)

Comprehensive pharmacological review of anastrozole and other aromatase inhibitors. Established that anastrozole achieves greater than 96% aromatase inhibition in vivo at the 1mg daily dose, with corresponding estradiol suppression of approximately 80%. Detailed the reversible, competitive binding mechanism and pharmacokinetic profile including the 40-50 hour half-life.
Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels

Burnett-Bowie SM, McKay EA, Lee H, Leder BZ

Bone (2009)

Studied the effects of anastrozole on bone health in older hypogonadal men. Found that anastrozole use was associated with increased bone resorption markers and decreased bone mineral density at the spine over 12 months. Underscored the critical role of estrogen in male bone metabolism and the need for caution with prolonged aromatase inhibitor use.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.